{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T05:16:55Z","timestamp":1769318215689,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anales de Pediatr\u00eda (English Edition)"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.anpede.2025.503995","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T12:32:34Z","timestamp":1768307554000},"page":"503995","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advanced therapies in pediatric genetic diseases"],"prefix":"10.1016","volume":"104","author":[{"given":"Eduardo F.","family":"Tizzano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.anpede.2025.503995_bib0005","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.medcli.2018.03.001","article-title":"Advanced therapies in rare diseases: the example of spinal muscular atrophy","volume":"151","author":"Tizzano","year":"2018","journal-title":"Med Clin (Barc)."},{"key":"10.1016\/j.anpede.2025.503995_bib0010","first-page":"35","article-title":"Avances gen\u00e9ticos en enfermedades respiratorias","volume":"11","author":"Tizzano","year":"2018","journal-title":"Med Resp."},{"key":"10.1016\/j.anpede.2025.503995_bib0015","article-title":"The diagnosis communication process in spinal muscular atrophy: a cross-cutting view of the new challenges facing the therapeutic era","volume":"1","author":"Rovira-Moreno","year":"2023","journal-title":"Genet Med Open."},{"key":"10.1016\/j.anpede.2025.503995_bib0020","unstructured":"BOE.es. BOE-A-2009-12002. Real Decreto 1015\/2009, de 19 de junio, por el que se regula la disponibilidad de medicamentos en situaciones especiales [accessed 05 Sep 2025]. Available from: https:\/\/www.boe.es\/buscar\/doc.php?id=BOE-A-2009-12002."},{"key":"10.1016\/j.anpede.2025.503995_bib0025","unstructured":"Clinicaltrials.gov. Glossary of common site terms [accessed 05 Sep 2025]. Available from: https:\/\/clinicaltrials.gov\/ct2\/about-studies\/glossary."},{"key":"10.1016\/j.anpede.2025.503995_bib0030","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","article-title":"Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases","volume":"28","author":"Calucho","year":"2018","journal-title":"Neuromuscul Disord."},{"key":"10.1016\/j.anpede.2025.503995_bib0035","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/1535370217750088","article-title":"Biomarker definitions and their applications","volume":"243","author":"Califf","year":"2018","journal-title":"Exp Biol Med (Maywood)."},{"key":"10.1016\/j.anpede.2025.503995_bib0040","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Terapias avanzadas. 2025 [accessed 05 Sep 2025]. Available from: https:\/\/www.aemps.gob.es\/medicamentos-de-uso-humano\/terapias-avanzadas\/."},{"key":"10.1016\/j.anpede.2025.503995_bib0045","unstructured":"European Medicines Agency. Committee for Advanced Therapies (CAT) [accessed 05 Sep 2025]. Available from: https:\/\/www.ema.europa.eu\/en\/committees\/committee-advanced-therapies-cat."},{"key":"10.1016\/j.anpede.2025.503995_bib0050","unstructured":"European Medicines Agency. Advanced therapy medicinal products: Overview. ema.europa.eu [accessed 05 Sep 2025]. Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/advanced-therapy-medicinal-products-overview."},{"key":"10.1016\/j.anpede.2025.503995_bib0055","first-page":"151","article-title":"State-of-the-art human gene therapy: part II. Gene therapy strategies and clinical applications","volume":"18","author":"Wang","year":"2014","journal-title":"Discov Med."},{"key":"10.1016\/j.anpede.2025.503995_bib0060","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.anpede.2025.503995_bib0065","first-page":"1276","article-title":"A systematic review of adeno-associated virus gene therapies in neurology: the need for consistent safety monitoring of a promising treatment","volume":"93","author":"Horton","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"10.1016\/j.anpede.2025.503995_bib0070","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.omtm.2020.06.022","article-title":"Ready for repair? Gene editing enters the clinic for the treatment of human disease","volume":"18","author":"Ernst","year":"2020","journal-title":"Mol Ther Methods Clin Dev."},{"key":"10.1016\/j.anpede.2025.503995_bib0075","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/gt.2017.66","article-title":"Will rising prices and budget constraints prevent patients from accessing novel gene therapies?","volume":"24","author":"Kent","year":"2017","journal-title":"Gene Ther."},{"key":"10.1016\/j.anpede.2025.503995_bib0080","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s43586-023-00200-7","article-title":"Mitochondrial gene editing","volume":"3","author":"Shoop","year":"2023","journal-title":"Nat Rev Methods Primers."},{"key":"10.1016\/j.anpede.2025.503995_bib0085","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/mus.23904","article-title":"Project Cure Spinal Muscular Atrophy Investigators Network. SMA valiant trial: a prospective, double-blind, placebo-controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy","volume":"49","author":"Kissel","year":"2014","journal-title":"Muscle Nerve."},{"key":"10.1016\/j.anpede.2025.503995_bib0090","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.anpede.2025.503995_bib0095","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/gt.2017.52","article-title":"The clinical landscape for SMA in a new therapeutic era","volume":"24","author":"Talbot","year":"2017","journal-title":"Gene Ther."},{"key":"10.1016\/j.anpede.2025.503995_bib0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103489","article-title":"The myotonic dystrophy type 1 drug development pipeline: 2022 edition","volume":"28","author":"Pascual-Gilabert","year":"2023","journal-title":"Drug Discov Today."},{"key":"10.1016\/j.anpede.2025.503995_bib0105","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature05756","article-title":"PTC124 targets genetic disorders caused by nonsense mutations","volume":"447","author":"Welch","year":"2007","journal-title":"Nature."},{"key":"10.1016\/j.anpede.2025.503995_bib0110","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/s41392-023-01439-y","article-title":"Targeting protein modifications in metabolic diseases: molecular mechanisms and targeted therapies","volume":"8","author":"Wu","year":"2023","journal-title":"Signal Transduct Target Ther."},{"key":"10.1016\/j.anpede.2025.503995_bib0115","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/s41431-019-0415-4","article-title":"Perspectives in genetic counseling for spinal muscular atrophy in the new therapeutic era: early pre-symptomatic intervention and test in minors","volume":"27","author":"Serra-Juhe","year":"2019","journal-title":"Eur J Hum Genet."},{"key":"10.1016\/j.anpede.2025.503995_bib0120","article-title":"In utero therapies, the next frontier","volume":"24","author":"Kolarova","year":"2025","journal-title":"Am J Med Genet C Semin Med Genet."},{"key":"10.1016\/j.anpede.2025.503995_bib0125","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awaf123","article-title":"In utero therapy for spinal muscular atrophy: closer to clinical translation","author":"Tizzano","year":"2025","journal-title":"Brain."}],"container-title":["Anales de Pediatr\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S234128792500465X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S234128792500465X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T16:24:51Z","timestamp":1769012691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S234128792500465X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S234128792500465X"],"URL":"https:\/\/doi.org\/10.1016\/j.anpede.2025.503995","relation":{},"ISSN":["2341-2879"],"issn-type":[{"value":"2341-2879","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advanced therapies in pediatric genetic diseases","name":"articletitle","label":"Article Title"},{"value":"Anales de Pediatr\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anpede.2025.503995","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.anpedi.2025.503995","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Asociaci\u00f3n Espa\u00f1ola de Pediatr\u00eda.","name":"copyright","label":"Copyright"}],"article-number":"503995"}}